Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP

Brave Asset Management Inc. lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 67.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,234 shares of the company's stock after selling 23,500 shares during the quarter. Brave Asset Management Inc.'s holdings in CRISPR Therapeutics were worth $613,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Mcguire Capital Advisors Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $25,000. Versant Capital Management Inc boosted its holdings in CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company's stock valued at $25,000 after purchasing an additional 296 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at about $26,000. Rothschild Investment LLC grew its stake in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on CRSP. Citizens Jmp restated a "market outperform" rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Monday, July 6th. UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 12th. Citigroup boosted their target price on shares of CRISPR Therapeutics from $82.00 to $88.00 and gave the stock a "buy" rating in a research report on Tuesday. Sanford C. Bernstein lifted their price target on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a "market perform" rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut CRISPR Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, July 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $68.06.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, signaling continued confidence in CRISPR Therapeutics’ development pipeline and long-term commercial potential. Piper Sandler Reaffirms Their Buy Rating on CRISPR Therapeutics AG
• Positive Sentiment: Bullish commentary highlighted potential CASGEVY sales growth and expansion into in vivo gene editing through CTX310, which could broaden CRSP’s future revenue opportunities if clinical and commercial milestones are achieved. CRISPR Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. However, the firm still expects CRSP to remain unprofitable in 2026 and 2027.
• Negative Sentiment: Brookline reduced its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and lowered its FY2026 estimate to a loss of $5.63 from $5.36. Both forecasts are weaker than the broader current-year consensus loss estimate of $4.90, potentially weighing on sentiment.
• Negative Sentiment: The same analyst modestly cut projected profits for FY2028, FY2029 and FY2030, suggesting a slightly less optimistic view of CRSP’s long-term earnings ramp. Despite those reductions, the estimates still imply a transition from losses to profitability beginning in FY2028.

Insider Transactions at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the company's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by corporate insiders.

CRISPR Therapeutics Price Performance

CRSP opened at $51.64 on Friday. The company has a quick ratio of 17.96, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The company's 50-day moving average price is $52.42 and its 200 day moving average price is $52.30. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of -10.85 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The company had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -4.65 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source